➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Merck
Express Scripts
Colorcon
Baxter

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,064,875

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,064,875 protect, and when does it expire?

Patent 10,064,875 protects IMPOYZ and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: 10,064,875
Title:Topical formulations comprising a steroid
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s): Ubaidulla; Udhumansha (Namakkal, IN), Kandavilli; Sateesh (Plainsboro, NJ), Vairale; Ajay Sunil (Hyderabad, IN), Wayne; Jeffrey A. (Markham, CA), Nalamothu; Vijendra (Basking Ridge, NJ), Meghal; Mistry (Ahmedabad, IN), Pakunlu; Refika Isil (Highland Park, NJ)
Assignee: PROMIUS PHARMA LLC (Princeton, NJ)
Application Number:15/928,332
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,064,875
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 10,064,875

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Encore Dermat IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF MODERATE PLAQUE PSORIASIS   Start Trial
Encore Dermat IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PLAQUE PSORIASIS   Start Trial
Encore Dermat IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y PSORIASIS   Start Trial
Encore Dermat IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER   Start Trial
Encore Dermat IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,064,875

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 2473161   Start Trial
European Patent Office 2473161   Start Trial
European Patent Office 3141246   Start Trial
Spain 2637447   Start Trial
Japan 2013503203   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Johnson and Johnson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.